3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
2
Terminated
1
Not yet recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
5
Thoracic
1
Plasma cell
1
Other solid neoplasm
1
Other hematologic neoplasm
1
Myeloid
1
Lymphoid
1
Genitourinary
1
Gastrointestinal
1
Classical hematology
1
Conditions
Neoplasms
1
Neoplasm Metastasis
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
Carboplatin
158
Pemetrexed
135
Cisplatin
115
pembrolizumab
99
Docetaxel
94
Paclitaxel
89
Gemcitabine
63
Erlotinib Hydrochloride
60
Radiotherapy
55
Nivolumab
55
Bevacizumab
46
Etoposide
42
atezolizumab
33
Radiosurgery
33
durvalumab
28
Cyclophosphamide
22
Vinorelbine
21
Ipilimumab
21
Radiation
20
Taxes
17
130-nm albumin-bound paclitaxel
17
Albumin-Bound Paclitaxel
16
Gefitinib
14
Irinotecan
13
Drug Therapy
13
osimertinib
12
avelumab
12
Magnetic Resonance Spectroscopy
12
Dexamethasone
12
Cetuximab
12
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
neratinib
×
Thoracic
×
Clear all
NCT01953926
2024-03-12
SUMMIT
Puma Biotechnology, Inc.
Phase 2
Terminated
582 enrolled
27 charts